

RESEARCH ARTICLE

Open Access



# Genotype and phenotype correlations in Iranian patients with hyperinsulinaemic hypoglycaemia

Senthil Senniappan<sup>1</sup>, Atefeh Sadeghizadeh<sup>2\*</sup>, Sarah E Flanagan<sup>3</sup>, Sian Ellard<sup>3</sup>, Mahin Hashemipour<sup>4</sup>, Majid Hosseinzadeh<sup>5</sup>, Mansour Salehi<sup>6</sup> and Khalid Hussain<sup>7,8</sup>

## Abstract

**Background:** Hyperinsulinaemic hypoglycaemia (HH) is a group of clinically and genetically heterogeneous disorders characterized by unregulated insulin secretion. Abnormalities in nine different genes (*ABCC8*, *KCNJ11*, *GLUD1*, *GCK*, *HADH*, *SLC16A1*, *HNF4A*, *UCP2* and *HNF1A*) have been reported in HH, the most common being *ABCC8* and *KCNJ11*. We describe the genetic aetiology and phenotype of Iranian patients with HH.

**Methods:** Retrospective clinical, biochemical and genetic information was collected on 23 patients with biochemically confirmed HH. Mutation analysis was carried out for the ATP-sensitive potassium ( $K_{ATP}$ ) channel genes (*ABCC8* and *KCNJ11*), *GLUD1*, *GCK*, *HADH* and *HNF4A*.

**Results:** 78 % of the patients were identified to have a genetic cause for HH. 48 % of patients had mutation in *HADH*, whilst *ABCC8/KCNJ11* mutations were identified in 30 % of patients. Among the diazoxide-responsive patients (18/23), mutations were identified in 72 %. These include two novel homozygous *ABCC8* mutations. Of the five patients with diazoxide-unresponsive HH, three had homozygous *ABCC8* mutation, one had heterozygous *ABCC8* mutation inherited from an unaffected father and one had homozygous *KCNJ11* mutation. 52 % of children in our cohort were born to consanguineous parents. Patients with *ABCC8/KCNJ11* mutations were noted to be significantly heavier than those with *HADH* mutation ( $p = 0.002$ ). Our results revealed neurodevelopmental deficits in 30 % and epilepsy in 52 % of all patients.

**Conclusions:** To the best of our knowledge, this is the first study of its kind in Iran. We found disease-causing mutations in 78 % of HH patients. The predominance of *HADH* mutation might be due to a high incidence of consanguineous marriage in this population. Further research involving a larger cohort of HH patients is required in Iranian population.

**Keywords:** Hyperinsulinaemic hypoglycaemia, *HADH* (hydroxyacyl-CoA-dehydrogenase), Diazoxide

## Background

Hyperinsulinaemic hypoglycaemia (HH) is a group of clinically and genetically heterogeneous disorders characterized by dysregulation of insulin secretion by pancreatic  $\beta$ -cells [1]. Early diagnosis and treatment is important to prevent permanent brain damage [2]. HH

can be either transient or persistent; transient forms of HH are usually secondary to conditions such as maternal diabetes mellitus or intra-uterine growth retardation [1]. The incidence of HH can vary from 1 in 35,000–40,000 in the general population [3] to 1 in 2,500 in some communities with high rates of consanguinity [4].

The clinical presentation can be varied ranging from completely asymptomatic, mild disease to severe disease unresponsive to medication needing surgical intervention [5]. The HH due to recessive mutations in *ABCC8/KCNJ11* is usually severe and requires high

\*Correspondence: a.sadeghizadeh@gmail.com

<sup>2</sup> Department of Pediatrics, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran  
Full list of author information is available at the end of the article

concentrations of intravenous glucose to maintain normoglycaemia [5]. Hypoglycemic symptoms may vary from being non-specific (such as poor feeding, lethargy and irritability) to severe (such as apnea, seizures or coma). Macrosomia is a common feature in infants, but not all babies with HH are macrosomic [6]. There are two histological subtypes of CHI: diffuse and focal [7]. The diffuse form is inherited in an autosomal recessive (or dominant) manner whereas the focal form is sporadic in inheritance. The first line of medical therapy in HH includes diazoxide, which binds to the intact SUR1 component of the  $K_{ATP}$  channels and prevents depolarization of the  $\beta$ -cell membrane and insulin secretion [1].

HH is caused by mutations in the key genes that are involved in regulation of insulin secretion from the pancreatic  $\beta$ -cells. So far, mutations in *ABCC8*, *KCNJ11*, *GLUD1*, *GCK*, *HADH*, *SLC16A1*, *HNF4A*, *UCP2* and *HNF1A* have been identified to be involved in the pathogenesis of HH [1, 8]. The most common causes of diffuse medically unresponsive HH are mutations in *ABCC8* and *KCNJ11*. These two genes encode for the SUR1 (sulphonylurea receptor 1 subunit) and Kir6.2 (inward-rectifying potassium channel pore-forming subunit) proteins, respectively which constitute the  $K_{ATP}$  channel of the pancreatic  $\beta$ -cell membrane [2].

The inactivating mutations in *ABCC8/KCNJ11* reduce or completely abolish the activity of the  $K_{ATP}$  channel, leading to unregulated insulin release despite severe hypoglycaemia [9]. The recessive inactivating mutations in *ABCC8* and *KCNJ11* usually cause severe HH, which is unresponsive to medical treatment with diazoxide. The molecular basis of recessive inactivating *ABCC8* and *KCNJ11* mutations involve defects in  $K_{ATP}$  channel biogenesis and turnover, channel trafficking from the ER and Golgi apparatus to the plasma membrane and alterations of channels in response to nucleotide regulation and open state frequency [10]. Dominant inactivating mutations in *ABCC8* and *KCNJ11* usually cause HH with a milder phenotype [11].

Hyperinsulinism–hyperammonaemia syndrome (HI/HA), the second most common form of HH is associated with activating missense mutations in *GLUD1*, which encodes the mitochondrial matrix enzyme, glutamate dehydrogenase (GDH). Patients present with recurrent symptomatic postprandial hypoglycaemia following protein-rich meals (leucine-sensitive hypoglycaemia) as well as fasting hypoglycaemia accompanied by asymptomatic elevations of plasma ammonia [12]. Mutations in *HNF4A*, *HNF1A* and *GCK* cause maturity-onset diabetes of the young (MODY) as well HH [8, 13].

Mutations in the mitochondrial *HADH* gene (encoding the enzyme L-3-hydroxyacyl-coenzyme A dehydrogenase, HADH), are a rare cause of HH [14]. This enzyme

catalysis the conversion of L-3-hydroxyacyl-CoAs of variable chain length to their corresponding 3-ketoacyl-CoAs and exerts highest activity to 3-hydroxybutyryl-CoA. *HADH* mutations can lead either to severe neonatal HH or to mild late onset HH [15]. All patients reported so far have responded to diazoxide and some had abnormal acylcarnitine metabolites (raised plasma hydroxybutyrylcarnitine and urinary 3-hydroxyglutarate levels). Protein sensitivity has been demonstrated in patients with *HADH* mutations [16] and this has been confirmed in the *HADH* knockout mouse [17]. However the precise mechanism of dysregulated insulin secretion in patients with a *HADH* deficiency is not understood but might involve an interaction between GDH and *HADH* [17]. Genetic analysis for *HADH* gene is recommended in patients with diazoxide responsive HH from consanguineous families, who are negative for mutations in the  $K_{ATP}$  channels [18].

Although clinical characteristics and genetic etiology of HH patients have been described in some studies [19–21], little is known about HH in the Iranian population with a high rate of consanguineous marriages [22]. The aim of this study was to investigate genotype/phenotype correlations in a sample of Iranian patients with HH from Isfahan.

## Methods

In this cross-sectional study, we collected data on the patients who visited the pediatric endocrinology outpatient clinics and the infants who were referred to Al-Zahra Hospital from September 1998 to July 2012. All infants and children were diagnosed with HH based on clinical and biochemical criteria [2]. Patients with a secondary cause of HH such as perinatal asphyxia, prematurity, intra-uterine growth restriction, and syndromic forms were excluded. The clinical data included age at presentation, birth weight, medications, neonatal history, epilepsy and neurological deficits, family history, history of hypoglycaemia following protein-rich meals and consanguinity of parents. Serum ammonia level was checked in all patients.

Children were defined as being responsive to diazoxide when (a) feeding with normal frequency and volume (b) able to fast appropriately for age and maintain normal blood glucose levels (c) serum insulin level low or undetectable at the end of the fast (d) appropriate increase in serum fatty acids and ketone bodies at the end of the fast [2]. Diazoxide-unresponsive patients either underwent near total pancreatectomy or were managed with combinations of octreotide and diazoxide along with high calorie feeds.

Written informed consent for genetic tests was obtained from parents of all patients. The study was

reviewed and approved by the Ethical Committee of Isfahan University of Medical Sciences.

Genomic DNA was extracted from peripheral leukocytes using standard procedures. All exons and intron-exon boundaries of *ABCC8*, *KCNJ11*, *HADH*, *GLUD1*, *HNF4A* and *GCK* genes were amplified by PCR. The products were sequenced using a BigDye Terminator v3.1 Cycle sequencing Kit on an ABI 3730XL Analyzer (Applied Biosystems, Foster City, CA, USA) and sequences were compared with the reference sequence (NM\_000525 for *KCNJ11*, NM\_000352.3 for *ABCC8*, and NM\_000162.3 for *GCK*) using Chromas (V.2.01, Technelysium Pty Ltd, Tewantin QLD, Australia) or Mutation Surveyor software V3.24 (Softgenetics, State College, PA, USA). Mutation testing was done on parental samples when a mutation was identified in the child. If no mutation was identified, testing for a partial/whole gene deletion was undertaken using multiplex ligation-dependent probe amplification (MLPA).

#### Statistical analysis

Data are presented as mean  $\pm$  standard deviation and frequency. The independent sample t test was used to assess continuous variables between two groups. The Mann-Whitney test was used for data that were not normally distributed. Analyses were performed using SPSS (IL, USA, version 19.0). Significant level was set as  $P < 0.05$ .

#### Results

Twenty-three patients with HH with age ranging from 1 month to 21 years were included in this study. One patient with achondroplasia and three children with secondary HH due to intra-uterine growth restriction were excluded. The age at presentation ranged from neonatal period (day 1 of life) to 3 years. Eleven (47 %) of the patients were noted to be symptomatic within the first 48 h after birth. The most common clinical symptom was seizure (82 %). All patients except two children were born at full term. The mean birth weight was  $3,423 \pm 757$  g (with a range of 1,700–5,000 g). Only five patients (21 %) were macrosomic. Ten (43 %) of patients were female. 12 (52 %) children with HH were born to consanguineous couples. Two families had two affected children.

A high frequency (30 %) of neurodevelopmental delay was observed in these patients. Furthermore, 12 (52 %) patients suffered from epilepsy. None of the patients had hyperammonemia.

A total number of 18 (78 %) patients responded to diazoxide. Five diazoxide-unresponsive patients underwent near total pancreatectomy. One of them died at 4 months of age due to thromboembolism in the post-operative period. One other patient, who was managed

with combinations of octreotide and diazoxide, died at 3 months of age due to sepsis. Clinical characteristics and gene mutations of these patients were summarized in Table 1.

Disease causing mutations were identified in 78 % of the patients (48 % had *HADH* mutation, 26 % had *ABCC8* and 4 % had *KCNJ11* mutation) (Fig. 1). Of the five with diazoxide-unresponsive HH, three had homozygous *ABCC8* mutation, one had heterozygous *ABCC8* mutation, which was inherited from an unaffected father, and one had homozygous *KCNJ11* mutation. All three diazoxide unresponsive patients with homozygous *ABCC8* mutation were managed by subtotal pancreatectomy. One of these patients needed insulin due to hyperglycemia in the post-operative period. The other two patients were euglycemic on a small (5 mg/kg/day) dose of diazoxide. One patient with a paternally inherited mutation was treated non-surgically with octreotide and diazoxide. One patient with homozygous *KCNJ11* mutation was managed by total pancreatectomy.

Interestingly two patients with a novel homozygous intronic *ABCC8* mutation were diazoxide responsive and HH resolved by 4 years of age in one of the two patients. The mechanism of this is not clear.

The same homozygous *HADH* mutation was identified in 11 children with diazoxide-responsive HH [frameshift mutation c.617delA, which is a deletion of an A nucleotide at position 617 and is predicted to result in a premature termination at codon 219 (p.K206fsX14)]. This included two affected siblings in two different families. Eight (72 %) children with *HADH* mutation had a history of hypoglycemia following protein-rich meals, although no formal protein load test was done in these patients.

Infants with *ABCC8/KCNJ11* mutations were heavier at birth in comparison to the patients with *HADH* mutation ( $4,190 \pm 550$  g vs.  $3,255 \pm 318$  g,  $P = 0.002$ ). The mean age of presentation of patients with a *HADH* mutation was 99.1 days in comparison to 1.14 days in patients with *ABCC8* mutations; the difference was statistically significant ( $P = 0.004$ ).

#### Discussion


In this study, 78 % of patients with HH from Isfahan, Iran were noted to have disease-causing mutations. It is very interesting to note that *HADH* mutation was the commonest genetic cause in this cohort (48 %) as opposed to the *ABCC8* mutations, which was noted only in 26 % of patients. The higher incidence of patients with *HADH* mutation accounted for the higher rate of diazoxide responsiveness in this group (78 %). All diazoxide-unresponsive patients in this series had identifiable mutations (*ABCC8/KCNJ11*), whilst no mutation was identified in 28 % of diazoxide-responsive patients.

**Table 1 Clinical characteristics and genetic mutations of 23 Iranian patients with hyperinsulinaemic hypoglycaemia**

Patient number	Gender (F = female, M = male)	Gestation- term	Birth weight (g)	Age of onset of hypoglycaemia	Epilepsy	Neurode-velopmental delay	Consan- guineous parents	Treatment		Geno- type	Mutation	Maternal/ paternal genotype	Follow up
								Diazoxide responsive	Octreo- tide responsive				
<i>ABCC8</i>													
1	F	Yes	3,280	2 days	No	No	No	Yes	Yes	Heterozy- gous	c.2041-21G>A (splicing)	None/het- erozygous	Died at 3 months of age
2	F	Yes	3,750	1 day	Yes	Yes	No	Yes	Yes	Homozy- gous	p.R1494W (mis- sense)	Heterozy- gous/het- erozygous	Needed insulin
3	F	Yes	4,200	1 day	Yes	No	Yes	Yes	Yes	Homozy- gous	p.W143X (non- sense)	Heterozy- gous/het- erozygous	Needed diazoxide
4	F	Yes	5,000	1 day	No	No	Yes	Yes	Yes	Homozy- gous	p.G1376R (mis- sense)	Heterozy- gous/het- erozygous	Needed diazoxide
5	M	Yes	4,200	1 day	No	No	Yes	Yes	Yes	Homozy- gous	c.2697+5G>A (intron 22, novel splic- ing)	Heterozy- gous/het- erozygous	On diazox- ide
6	M	Yes	4,500	1 day	No	No	Yes	Yes	Yes	Homozy- gous	c.2697+5G>A (intron 22, novel splic- ing)	Heterozy- gous/het- erozygous	Resolved by 4 years of age
<i>KCNJ11</i>													
7	M	Yes	4,400	1 day	No	No	Yes	Yes	Yes	Com- pound het- erozy- gous	p.P34OH (mis- sense) and p.F117del (novel in- frame)	Heterozy- gous/het- erozygous	Died at 4 months of age
<i>HADH</i>													
8	M	Yes	2,860	3 months	Yes	No	Yes	Yes	Yes	Homozy- gous	delA617c (frameshift)	Heterozy- gous/het- erozygous	On diazox- ide
9	F	Yes	3,000	1 year	No	No	Yes	Yes	Yes	Homozy- gous	delA617c (frameshift)	Heterozy- gous/het- erozygous	Stopped diazoxide/ no relapse
10	M	Yes	2,900	1 day	Yes	Yes	Yes	Yes	Yes	Homozy- gous	delA617c (frameshift)	Heterozy- gous/het- erozygous	On diazox- ide

Table 1 continued

Patient number	Gender (F = female, M = male)	Gestation-term	Birth weight (g)	Age of onset of hypoglycaemia	Epilepsy	Neurodevelopmental delay	Consanguineous parents	Treatment		Geno-type	Mutation	Maternal/paternal genotype	Follow up
								Diazoxide responsive	Octreotide responsive				
11	F	Yes	3,650	4 days	No	No	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
12	M	Yes	3,600	3 months	Yes	Yes	Yes	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
13	M	Yes	3,100	1.5 months	Yes	Yes	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
14	M	Yes	2,900	7.5 months	No	No	Yes	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
15	F	Yes	3,200	1 day	Yes	No	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
16	M	Yes	3,600	3 months	Yes	Yes	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
17	M	Yes	3,500	3 months	Yes	Yes	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
18	M	Yes	3,500	3 months	Yes	No	No	Yes	Yes	Homozygous	delA617.c (frameshift)	Heterozygous/heterozygous	On diazoxide
No mutation													
19	M	No	1,700	3 years	No	No	Yes	Yes	Yes				Tapered diazoxide/no relapse
20	M	No	2,050	1 day	Yes	No	No	Yes	Yes				On diazoxide
21	F	Yes	2,800	9 months	No	No	No	Yes	Yes				On diazoxide
22	F	Yes	3,300	5 months	Yes	Yes	Yes	Yes	Yes				On diazoxide
	F	Yes	3,750	1 day	No	No	No	Yes	Yes				On diazoxide



In contrast to these observations, several other studies suggest a major role of  $K_{ATP}$  channel in the pathogenesis of patients with HH [19, 21, 23]. In a large series of 417 patients with HH, mutations were identified in 91 % of diazoxide-unresponsive probands, and in 47 % of diazoxide-responsive patients [20]. However, only 2 cases (4 % of diazoxide-responsive probands) were positive for *HADH* mutation. In another large series involving 300 patients with HH [19], mutations were identified in 45.3 % of patients and *ABCC8/KCNJ11* mutations were noted to be the commonest. Among the 22.4 % of patients who had mutations in the diazoxide responsive group, only 3 patients (1 % of all cases) had *HADH* mutation [19].

In keeping with previous observation [14, 19, 20], all patients with *HADH* mutation in this group were diazoxide responsive, whilst the majority of patients (71 %) with *ABCC8/KCNJ11* mutations were diazoxide-unresponsive. As shown previously, patients with *HADH* mutation were diagnosed later and were of normal birth weight in comparison to *ABCC8* mutations [19, 24].

The clinical presentation of patients with heterozygous (autosomal dominant) *ABCC8* mutations is variable, ranging from mild medically responsive forms to severe early-onset HH and the vast majority of patients who do not respond to diazoxide have homozygous *ABCC8* mutations [20]. We observed that three of the five patients with severe HH had homozygous *ABCC8* mutations. Interestingly a novel homozygous *ABCC8* mutation was identified in two patients with a mild form of HH that resolved completely. The precise mechanism of the course of HH in these patients is unclear.

Genetic analysis of *HADH* is generally suggested in patients with diazoxide responsive HH from consanguineous families, who are negative for mutations in the  $K_{ATP}$  channels [18]. The Iranian population like some other populations, has a high level of consanguinity [22]. A higher rate of consanguineous marriages may favor the onset and increased frequency of autosomal recessive diseases in a population [22]. Parental consanguinity was observed in 45 % (5/11) of patients with *HADH* mutation in our cohort. Hence the higher incidence of *HADH* mutation in our group of patients is very likely related to the higher rate of consanguineous marriages in these families. Also 80 % (4/5) of children with homozygous *ABCC8* mutation had consanguineous parents.

Our results showed neurodevelopmental deficits in 30 % of the patients and epilepsy in 52 % of all cases. The prevalence of mental retardation and epilepsy was reported to be 31 and 15 %, respectively in a group of patients with HH in Austria [25]. Long-term follow up of 114 patients with HH showed poor general outcome with a high degree of psychomotor or mental retardation (44 %) or epilepsy (25 %) [26]. Another study from Argentina reported neurological impairment in 38 % of children with HH [27], whereas a study from Greece which followed up 13 HH patients reported a good neurological outcome without any psychomotor retardation [28]. It is well known that neonatal hypoglycemia is associated with neurodevelopmental complications [29–31].

Our study has several limitations. Firstly it includes a small number of patients from Isfahan, which may not be representative of the whole Iranian population. Secondly the data was collected on a retrospective basis from the

medical records. Finally, an 18-F DOPA PET/CT scan was not available to differentiate focal from diffuse lesion.

## Conclusion

This study first of its kind from Iran, demonstrates disease-causing mutations in 78 % of HH patients from Isfahan. Majority of these patients (78 %) responded to medical therapy with diazoxide. A high rate (48 %) of *HADH* mutation is seen in this population that might be attributed to a high rate of consanguineous marriages. Data shows a suboptimal long-term outcome with a high degree of neurodevelopmental deficits and epilepsy in these patients. Further research with a larger number of patients is necessary to identify the mechanism(s) of HH in Iranian population.

## Abbreviations

GCK: glucokinase; GDH: glutamate dehydrogenase; HI/HA: hyperinsulinism–hyperammonaemia syndrome; HH: hyperinsulinaemic hypoglycaemia; HADH: hydroxyacyl-coenzyme A dehydrogenase; HNF: hepatocyte nuclear factor; MLPA: multiplex ligation-dependent probe amplification; MODY: maturity onset diabetes of the young; PCR: polymerase chain reaction; K<sub>ATP</sub>: potassium ATP channel; SUR: sulphonylurea receptor.

## Authors' contributions

AH, MH, MH and MS collected the data and prepared the first draft. SEF and SE carried out the molecular genetic studies. AH performed the statistical analysis. SS and KH participated in the design of the study and revision of the manuscript. All authors read and approved the final manuscript.

## Author details

<sup>1</sup> Alder Hey Children's Hospital, Liverpool, UK. <sup>2</sup> Department of Pediatrics, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>3</sup> Institute Biomedical and Clinical Science, University of Exeter Medical School, Exeter EX2 5DW, UK. <sup>4</sup> Endocrinology and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>5</sup> Medical Genetics Laboratory, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. <sup>6</sup> Pediatric Inherited Disease Research Center (PIDRC), Isfahan University of Medical Sciences, Isfahan, Iran. <sup>7</sup> Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, UK. <sup>8</sup> Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children, London, UK.

## Acknowledgements

None.

## Compliance with ethical guidelines

## Competing interests

The authors declare that they have no competing interests.

Received: 29 October 2014 Accepted: 4 August 2015

Published online: 13 August 2015

## References

- Senniappan S, Shanti B, James C, Hussain K (2012) Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. *J Inherit Metab Dis* 35:589–601
- Senniappan S, Arya VB, Hussain K (2013) The molecular mechanisms, diagnosis and management of congenital hyperinsulinism. *Indian J Endocrinol Metab* 17:19–30
- Bruining GJ (1990) Recent advances in Hyperinsulinism and the pathogenesis of diabetes mellitus. *Curr Opin Pediatr* 2:758–765
- Mathew PM, Young JM, Abu-Osba YK, Mulhern BD, Hammoudi S, Hamdan JA et al (1988) Persistent neonatal hyperinsulinism. *Clin Pediatr (Phila)* 27:148–151
- Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, De Lonlay-Debeney P et al (2000) Practical management of hyperinsulinism in infancy. *Arch Dis Child Fetal Neonatal Ed* 82:F98–F107
- Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP et al (2007) Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. *PLoS Med* 4:e118
- Rahier J, Guiot Y, Sempoux C (2000) Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. *Arch Dis Child Fetal Neonatal Ed* 82:F108–F112
- Stanescu DE, Hughes N, Kaplan B, Stanley CA, De León DD (2012) Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. *J Clin Endocrinol Metab* 97(10):E2026–E2030
- Kane C, Shepherd RM, Squires PE, Johnson PR, James RF, Milla PJ et al (1996) Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. *Nat Med* 2:1344–1347
- Lin YW, MacMullen C, Ganguly A, Stanley CA, Shyng SL (2006) A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels. *J Biol Chem* 281:3006–3012
- Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, Thornton P et al (2008) Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. *J Clin Invest* 118:2877–2886
- Hsu BY, Kelly A, Thornton PS, Greenberg CR, Dilling LA, Stanley CA (2001) Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. *J Pediatr* 138:383–389
- Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT et al (2008) Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. *Diabetes* 57:1659–1663
- Clayton PT, Eaton S, Aynsley-Green A, Edginton M, Hussain K, Krywawych S et al (2001) Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion. *J Clin Invest* 108:457–465
- Martins E, Cardoso ML, Rodrigues E, Barbot C, Ramos A, Bennett MJ et al (2011) Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: the clinical relevance of an early diagnosis and report of four new cases. *J Inherit Metab Dis* 34:835–842
- Kapoor RR, James C, Flanagan SE, Ellard S, Eaton S, Hussain K (2009) 3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity. *J Clin Endocrinol Metab* 94:2221–2225
- Li C, Chen P, Palladino A, Narayan S, Russell LK, Sayed S et al (2010) Mechanism of hyperinsulinism in short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency involves activation of glutamate dehydrogenase. *J Biol Chem* 285:31806–31818
- Flanagan SE, Patch AM, Locke JM, Akcay T, Simsek E, Alaei M et al (2011) Genome-wide homozygosity analysis reveals HADH mutations as a common cause of diazoxide-responsive hyperinsulinemic-hypoglycemia in consanguineous pedigrees. *J Clin Endocrinol Metab* 96:E498–E502
- Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K (2013) Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. *Eur J Endocrinol* 168:557–564
- Snider KE, Becker S, Boyajian L, Shyng SL, MacMullen C, Hughes N (2013) Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. *J Clin Endocrinol Metab* 98:E355–E363
- Faletta F, Athanasakis E, Morgan A, Biarnés X, Fornasier F, Parini R et al (2013) Congenital hyperinsulinism: clinical and molecular analysis of a large Italian cohort. *Gene* 521:160–165
- Saadat M, Ansari-Lari M, Farhud DD (2004) Consanguineous marriage in Iran. *Ann Hum Biol* 31:263–269
- Park SE, Flanagan SE, Hussain K, Ellard S, Shin CH, Yang SW (2011) Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism. *Eur J Endocrinol* 164:919–926



24. Molven A, Matre GE, Duran M, Wanders RJ, Rishaug U, Njølstad PR et al (2004) Familial hyperinsulinemic hypoglycemia caused by a defect in the SCHAD enzyme of mitochondrial fatty acid oxidation. *Diabetes* 53:221–227
25. Mercimek-Mahmutoglu S, Rami B, Feucht M, Herle M, Rittinger O, Stoeckler-Ipsiroglu S et al (2008) Long-term follow-up of patients with congenital hyperinsulinism in Austria. *J Pediatr Endocrinol Metab* 21:523–532
26. Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E (2003) Long-term follow-up of 114 patients with congenital hyperinsulinism. *Eur J Endocrinol* 149:43–51
27. Cresto JC, Abdenur JP, Bergada I, Martino R (1998) Long-term follow up of persistent hyperinsulinaemic hypoglycaemia of infancy. *Arch Dis Child* 79:440–444
28. Dacou-Voutetakis C, Psychou F, Maniati-Christidis M (1998) Persistent hyperinsulinemic hypoglycemia of infancy: long-term results. *J Pediatr Endocrinol Metab* 11(Suppl 1):131–141
29. Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM (1999) Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. *J Pediatr* 134:492–498
30. Rovet JF, Ehrlich RM (1999) The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. *J Pediatr* 134:503–506
31. Avatapalle HB, Banerjee I, Shah S, Pryce M, Nicholson J, Rigby L et al (2013) Abnormal neurodevelopmental outcomes are common in children with transient congenital hyperinsulinism. *Front Endocrinol (Lausanne)* 4:60

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

